GlobeNewswire - News from California

CareTrust REIT Sets Fourth Quarter Earnings Call for Thursday, February 11, 2021

2021-02-06T00:51:18Z

SAN CLEMENTE, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- CareTrust REIT, Inc. (NASDAQ:CTRE) announced today that it plans to release its fourth quarter and full year 2020 financial results after the U.S. markets close on Wednesday, February 10, 2021. Representatives of CareTrust REIT��s management team will host a conference call to discuss the results and other current matters the following day.

Equillium Announces Closing of $30 Million Registered Direct Offering

2021-02-05T22:36:08Z

LA JOLLA, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the closing of its previously announced registered direct offering with life science institutional investment funds managed by Decheng Capital, to purchase 4,285,710 units (the ��Units��) from Equillium, with each Unit consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock. The purchase price per Unit was $7.00, priced above the market under Nasdaq rules. The warrants have an exercise price of $14.00 per share, are immediately exercisable, and will expire on the earlier of (i) the fifth anniversary of issuance, or (ii) the 15^th calendar date following the date on which Equillium closes a financing raising a minimum of $25 million at a price per share of no less than $25.00.? ?

Pacific Biosciences Grants Equity Incentive Award to New Employee

2021-02-05T22:00:00Z

MENLO PARK, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (��Pacific Biosciences�� or the ��Company��), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company��s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and restricted stock units (��RSU��) covering 50,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the ��2020 Inducement Plan��).

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2021-02-05T22:00:00Z

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to three new employees to purchase an aggregate of 38,000 shares of the Company��s common stock with an exercise price of $5.79 per share, the closing price of Assembly Bio��s common stock on February 1, 2021. The stock options were granted as material inducements to the new employees to accept the Company��s offers of employment.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2021-02-05T21:30:00Z

PALO ALTO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on February 1, 2021, the compensation committee of BridgeBio��s board of directors granted 11 new employees restricted stock units for an aggregate of 16,772 shares of the Company��s common stock. All of the above-described awards were made under BridgeBio��s 2019 Inducement Equity Plan (the Plan).

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2021-02-05T21:05:00Z

DUBLIN, Ireland, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and?neurodegenerative diseases, today announced that in connection with hiring three new employees, the compensation committee of the Company��s board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 75,000 ordinary shares of the Company. The options have an exercise price per share equal to $11.00, which was the closing trading price on February 1, 2021, the date of the grants. The inducement awards will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the date of grants and 1/48th of the underlying shares vesting monthly thereafter over 36 months. The options were granted pursuant to the Company��s 2020 Employment Inducement Incentive Plan, which was approved by the Company��s board of directors under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

SeaSpine Reports Granting of Inducement Awards

2021-02-05T21:05:00Z

CARLSBAD, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has issued inducement awards to nine non-executive employees.

HAGENS BERMAN, National Trial Attorneys, Alerts Triterras (TRIT) Investors to Fast Approaching Deadline, Investors with Significant Losses Should Contact Firm

2021-02-05T20:22:21Z

SAN FRANCISCO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Triterras, Inc. (NASDAQ: TRIT) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.

CLOV INVESTOR ALERT: Clover Health Investments (CLOV) Investors Urged to Contact HAGENS BERMAN, National Trial Attorneys; CLOV Admits Prior Knowledge of Undisclosed DOJ Inquiry & Announces Receipt of SEC Inquiry into Potential Securities Fraud

2021-02-05T20:17:49Z

SAN FRANCISCO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Hagens Berman encourages Clover Health Investments, Corp. (NASDAQ: CLOV) investors to submit their losses now.?The firm is investigating possible securities fraud and certain investors may have valuable claims.

End of Day Message

2021-02-05T18:35:00Z

LONDON, 05 Feb. 2021 (GLOBE NEWSWIRE) -- This is the End of Day Message for GlobeNewswire.

June 5 ��Cobra Day�� To Bring Largest Display of Shelby Cobras in Over 30 Years

2021-02-05T18:15:00Z

Martinez, CA event features sweepstakes to win a rare 50th Anniversary Shelby 289 FIA Cobra Roadster

Martinez, CA event features sweepstakes to win a rare 50th Anniversary Shelby 289 FIA Cobra Roadster

DUE TO OVERWHELMING SUPPORT FROM THE DOGECOIN COMMUNITY, KRONOS WILL MANUFACTURE ONE THOUSAND OF OUR AIRDOG PURIFIRS REBRANDED AS ��AIRDOGE�� AS A NUMBERED, LIMITED EDITION.

2021-02-05T18:12:46Z

Los Angeles, CA, Feb. 05, 2021 (GLOBE NEWSWIRE) -- LOS ANGELES, CA, February 5, 2021 (GLOBE NEWSWIRE) -- KRONOS ADVANCED TECHNOLOGIES, INC., (OTC MARKETS: KNOS) ("KNOS" or the "Company"), a revenue-generating, product development and production company that has significantly changed the way air is moved, filtered and sterilized reports today the release of a limited-edition air purifier due to an overwhelming, positive response from Reddit's Dogecoin community. This vibrant community showed tremendous support for our decision to add DOGE coin as an additional form of payment for our products, along with other major cryptocurrencies, such as Bitcoin, Ethereum, and Litecoin. We believe that part of this enthusiasm, in addition to the great need for our products, is due to Kronos becoming the first publicly traded Company to announce the acceptance of the DOGE coin.

KNDI 4-DAY INVESTOR DEADLINE: Hagens Berman Alerts Kandi Technologies Group (KNDI) Investors to February 9th Deadline in Securities Fraud Lawsuit, Investors with Losses Should Contact the Firm Now

2021-02-05T17:56:25Z

SAN FRANCISCO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Kandi Technologies Group, Inc. (NASDAQ: KNDI) investors to submit their losses now. A securities fraud class action has been filed and certain investors may have valuable claims.

The Roddenberry Foundation Donates $100,000 to the Comic-Con Museum

2021-02-05T17:27:07Z

Funding supports the Museum��s renovation and programming plans in anticipation of the 2021 opening of its physical space in San Diego; also recognizes the Museum��s efforts to highlight inclusivity, innovation and creativity while honoring the legacy of Star Trek creator Gene Roddenberry

Funding supports the Museum��s renovation and programming plans in anticipation of the 2021 opening of its physical space in San Diego; also recognizes the Museum��s efforts to highlight inclusivity, innovation and creativity while honoring the legacy of Star Trek creator Gene Roddenberry

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against 9F Inc. (JFU)

2021-02-05T16:00:00Z

LOS ANGELES, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (��GPM��) reminds investors of the upcoming?March 22, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased or otherwise acquired 9F Inc. (��9F�� or the ��Company��) (NASDAQ: JFU) securities: (a) pursuant and/or traceable to the registration statement and related prospectus in connection with the Company��s August 14, 2019 initial public offering (the ��IPO�� or ��Offering��); and/or (b) between August 14, 2019 and September 29, 2020, inclusive (the ��Class Period��).

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lizhi, Inc. (LIZI)

2021-02-05T16:00:00Z

LOS ANGELES, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (��GPM��) reminds investors of the upcoming?March 22, 2021?deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Lizhi Inc. (��Lizhi�� or the ��Company��) (NASDAQ: LIZI) American Depositary Shares (��ADSs�� or ��shares��) pursuant and/or traceable to the Company��s January 2020 initial public offering (��IPO�� or the ��Offering��).

Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium?

2021-02-05T14:00:00Z

�C Management to host webinar for analysts on Friday, Feb. 12, at 8:00 a.m. Eastern Time �C

�C Management to host webinar for analysts on Friday, Feb. 12, at 8:00 a.m. Eastern Time �C

PDF Solutions to Report Fourth Quarter and Fiscal Year 2020 Financial Results on February 18, 2021

2021-02-05T13:59:07Z

SAN JOSE, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- PDF Solutions, Inc. (Nasdaq: PDFS), a leading provider of smart manufacturing analytics and connectivity platforms for the semiconductor and electronics industries, announced that it?will release fourth quarter and fiscal year 2020 financial results after the market close on Thursday, February 18, 2021. John Kibarian, CEO, and Adnan Raza, CFO, will host a live teleconference on February 18, 2021, beginning at 2:00?p.m. Pacific Time / 5:00?p.m. Eastern Time to discuss the results. To?participate on?the call, please dial (877) 221-5831?within the United States and Canada, or?(706) 902-1220?outside of the United States and Canada.?You do not need a passcode, just reference the "PDF Solutions' Fourth Quarter and Fiscal Year 2020 Financial Results Call.�� ?The teleconference will be webcast simultaneously on the company��s website at?http://ir.pdf.com/webcasts.

Angion Biomedica Corp. Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement

2021-02-05T13:30:00Z

UNIONDALE, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the pricing of its initial public offering on February 4, 2021 of 5,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $80,000,000 million, before deducting the underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Angion. Angion has also granted the underwriters a 30-day option to purchase from Angion up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Angion��s common stock has been approved for listing on The Nasdaq Global Select Market and is expected to begin trading under the ticker symbol ��ANGN�� on February 5, 2021. The offering is expected to close on February 9, 2021, subject to satisfaction of customary closing conditions.

Oncocyte Announces Pricing of $35 Million Public Offering of Common Stock

2021-02-05T13:25:00Z

IRVINE, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it has priced the previously announced underwritten public offering of 7,780,000 shares of its common stock, at a public offering price of?$4.50?per share. The gross proceeds to the Company from this offering are expected to be approximately?$35.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. The offering is expected to close on or about?February 9, 2021, subject to satisfaction of customary closing conditions. The Company has granted the underwriters a 30-day option to purchase up to an additional 1,167,000 shares of its common stock at the public offering price.